Eric Albright
Denver, CONPI 1114989563
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,545 of the $4,001 with a category attached, or 63.6%. Sanofi-aventis U.S. LLC accounts for 70.2% of it on its own, with 18 other manufacturers making up the rest.
Across 88 payments — averaging $45.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$3K
- Amneal Pharmaceuticals LLC$200
- Amgen$193
- Johnson & Johnson$158
- AstraZeneca$113
- Merck$113
- plus $415 from 13 others
What the payments were for
- Consulting fees$2,54564%
- Food & beverage$1,44636%
- Education$110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 12 | $2,810 |
| Amneal Pharmaceuticals LLC | 18 | $200 |
| Amgen | 12 | $193 |
| Johnson & Johnson | 9 | $158 |
| AstraZeneca | 6 | $113 |
| Merck | 7 | $113 |
| Novo Nordisk | 4 | $76 |
| AbbVie | 3 | $71 |
| Mannkind Corporation | 3 | $48 |
| Lilly USA, LLC | 3 | $43 |
| Insulet Corporation | 3 | $42 |
| Medtronic | 1 | $22 |
| Ipsen Biopharmaceuticals, Inc | 1 | $22 |
| IBSA Pharma Inc. | 1 | $20 |
| Radius Health, Inc. | 1 | $19 |
| Boehringer Ingelheim | 1 | $15 |
| Senseonics, Incorporated | 1 | $14 |
| Companion Medical, Inc. | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DISEASE STATE$2,658
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humalog Kwikpen U-100Insulin Lispro | 95 | $39,293 |
| HumalogInsulin Lispro | 93 | $26,181 |
| Insulin Glargine-Yfgn | 176 | $21,638 |
| BaqsimiGlucagon | 14 | $8,541 |
| Humalog Junior KwikpenInsulin Lispro | 22 | $6,552 |
| Ultra-Fine Short Pen NeedlePen Needle, Diabetic | 48 | $2,485 |
| Levothyroxine Sodium | 108 | $1,956 |
| Ultra-Fine Mini Pen NeedlePen Needle, Diabetic | 26 | $1,421 |
| Hydrocortisone | 20 | $1,348 |
| Veo Insulin SyringeSyringe-Needle,insulin,0.5 Ml | 31 | $1,072 |
| Sure Comfort Pen NeedlePen Needle, Diabetic | 13 | $597 |
| Alendronate Sodium | 45 | $419 |
| Veo Insulin SyringeSyringe And Needle,insulin,1ml | 13 | $416 |
| Metformin Hcl | 35 | $395 |
| Atorvastatin Calcium | 14 | $260 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCHumalog, Baqsimi | $43 | $34,722107 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $200 | $1,956108 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in Coloradoon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.